Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials
Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition with limited pharmacological options. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as potential therapies for MASLD, but their efficacy and safety have not been compreh...
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2026-05-01
|
| Saila: | Diabetology & Metabolic Syndrome |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s13098-026-02179-z |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|